Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of 4SC-201 in relapsed or refractory Hodgkin lymphoma
2009-014699-24Phase 2Completed
- Sponsor
- 4SC AG
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Resminostat in Hodgkin lymphoma (HL), sponsored by 4SC AG. Primary endpoint: Objective response rate. Started Oct 2009; status: completed.
02
Drugs
Resminostat
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on 2009-014699-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014699-24.